About: Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $5.00 (-0.60%)
AVIR NASDAQ Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc share price
AVIR price activity
Last Price
$5.000
Change (24hr)
-0.03 USD (-0.60%)
Volume
98.36K
Volume (4w avg)
-
Open
$5.03
Day Range
$5.00 - $5.03
Previous Close
$5.03
Last Trade
13 Oct, 7:07 pm GMT+0
Delayed
13 Oct, 7:07 pm GMT+0
AVIR price performance
Delayed
13 Oct, 7:07 pm GMT+0
AVIR Market Signals